MX2013003452A - Conjugados de amatoxina con enlazantes mejorados. - Google Patents

Conjugados de amatoxina con enlazantes mejorados.

Info

Publication number
MX2013003452A
MX2013003452A MX2013003452A MX2013003452A MX2013003452A MX 2013003452 A MX2013003452 A MX 2013003452A MX 2013003452 A MX2013003452 A MX 2013003452A MX 2013003452 A MX2013003452 A MX 2013003452A MX 2013003452 A MX2013003452 A MX 2013003452A
Authority
MX
Mexico
Prior art keywords
conjugates
amatoxin
relates
improved linkers
linkers
Prior art date
Application number
MX2013003452A
Other languages
English (en)
Other versions
MX344010B (es
Inventor
Jan Anderl
Werner Simon
Christoph Mueller
Original Assignee
Heidelberg Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heidelberg Pharma Gmbh filed Critical Heidelberg Pharma Gmbh
Publication of MX2013003452A publication Critical patent/MX2013003452A/es
Publication of MX344010B publication Critical patent/MX344010B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con una terapia tumoral. En un aspecto, la presente invención se relaciona con conjugados de una amatoxina y una porción que se une al blanco, por ejemplo, un anticuerpo conectado por un enlazante que comprende una porción de urea, los cuales son útiles en el tratamiento del cáncer. En un aspecto más la invención se relaciona con una composición farmacéutica que comprende esos conjugados.
MX2013003452A 2010-09-30 2011-09-29 Conjugados de amatoxina con enlazantes mejorados. MX344010B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10012573A EP2436398B1 (en) 2010-09-30 2010-09-30 Amatoxin-conjugates with improved linkers
PCT/EP2011/004875 WO2012041504A1 (en) 2010-09-30 2011-09-29 Amatoxin-conjugates with improved linkers

Publications (2)

Publication Number Publication Date
MX2013003452A true MX2013003452A (es) 2013-08-29
MX344010B MX344010B (es) 2016-12-02

Family

ID=43127753

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003452A MX344010B (es) 2010-09-30 2011-09-29 Conjugados de amatoxina con enlazantes mejorados.

Country Status (16)

Country Link
US (1) US9399681B2 (es)
EP (2) EP2436398B1 (es)
JP (1) JP5977241B2 (es)
KR (1) KR102041166B1 (es)
CN (1) CN103153345B (es)
AU (1) AU2011307195B2 (es)
BR (1) BR112013007577B1 (es)
CA (1) CA2812460C (es)
ES (2) ES2402254T3 (es)
IL (1) IL225200A (es)
MX (1) MX344010B (es)
NZ (1) NZ608142A (es)
RU (1) RU2601411C2 (es)
SG (1) SG189189A1 (es)
UA (1) UA111341C2 (es)
WO (1) WO2012041504A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3192529T (lt) * 2009-04-08 2020-06-25 Faulstich, Heinz, Dr. Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
WO2013092983A2 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of polypeptides
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
EP2774624A1 (en) 2013-03-04 2014-09-10 Heidelberg Pharma GmbH Amatoxin derivatives
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
US10071169B2 (en) 2013-06-20 2018-09-11 Innate Pharma Enzymatic conjugation of polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
JP6321687B2 (ja) * 2014-03-10 2018-05-09 ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング アマトキシン誘導体
CA2957354A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Cysteine engineered antibodies and conjugates
US9751946B2 (en) 2014-09-12 2017-09-05 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
EA201790545A1 (ru) 2014-09-12 2017-07-31 Дженентек, Инк. Антитела и иммуноконъюгаты против her2
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
EP3215519A1 (en) 2014-11-06 2017-09-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
BR112017010324A2 (pt) 2014-11-20 2018-05-15 F. Hoffmann-La Roche Ag método para tratar ou retardar a progressão de um câncer em um indivíduo, moléculas, métodos para aumentar a função imune em um indivíduo e para selecionar um paciente para tratamento, kits, composição farmacêutica e usos de uma combinação de uma molécula
PL3268047T3 (pl) 2015-03-09 2024-03-18 Heidelberg Pharma Research Gmbh Nowe koniugaty amatoksyna-przeciwciało
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3222292A1 (en) * 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
MX2018012803A (es) 2016-04-20 2019-06-24 Hangzhou Dac Biotech Co Ltd Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular.
US10464969B2 (en) 2016-05-05 2019-11-05 Novartis Ag Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
US11013816B2 (en) 2016-05-31 2021-05-25 Sorrento Therapeutics, Inc. Antibody drug conjugates having derivatives of amatoxin as the drug
AU2017204139B2 (en) 2016-06-17 2018-08-09 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cells
MA45408A (fr) 2016-06-17 2019-04-24 Magenta Therapeutics Inc Compositions et procédés pour la déplétion des cellules cd117+
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
MX2019007604A (es) * 2016-12-23 2019-08-16 Heidelberg Pharma Res Gmbh Novedoso conjugado de amanitina.
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
WO2019030171A1 (en) 2017-08-07 2019-02-14 Heidelberg Pharma Gmbh NOVEL METHOD FOR SYNTHESIZING AMANITINES
BR112020001345A2 (pt) * 2017-08-07 2020-08-11 Heidelberg Pharma Gmbh método inovador para síntese de amanitinas
EP3738608A4 (en) * 2017-08-18 2021-12-08 Sichuan Baili Pharm Co. Ltd NON-NATURAL AMATOXIN TYPE ANTIBODY CONJUGATE
CA3095211A1 (en) * 2017-09-08 2019-03-14 Sichuan Baili Pharm Co. Ltd An amantin antibody conjugate
BR112020005605A2 (pt) 2017-09-22 2020-10-13 Heidelberg Pharma Research Gmbh novos conjugados de amanitina direcionados a psma
CN111601616A (zh) 2017-10-24 2020-08-28 美真达治疗公司 用于耗尽cd117+细胞的组合物和方法
AU2018355244A1 (en) 2017-10-24 2020-04-09 Crispr Therapeutics Ag Compositions and methods for the depletion of CD117+ cells
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
WO2019197654A1 (en) * 2018-04-13 2019-10-17 Heidelberg Pharma Research Gmbh Targeted amatoxin conjugate for the treatment of solid tumors
CN109796537A (zh) * 2019-02-28 2019-05-24 中国农业大学 一种β-鹅膏毒肽人工抗原及其制备方法与应用
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
AR120218A1 (es) * 2019-10-15 2022-02-02 Heidelberg Pharma Res Gmbh Conjugados de amatoxina y anticuerpo específico de linfocitos b
EP4213886A1 (en) 2020-09-18 2023-07-26 Araris Biotech AG Transglutaminase conjugation method with amino acid-based linkers
PE20231512A1 (es) 2020-10-25 2023-09-26 Araris Biotech Ag Medios y metodos para producir conjugados de ligador-anticuerpo
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
CN113980909B (zh) * 2021-11-16 2022-06-14 江南大学 一种α-鹅膏蕈碱人工抗原、单克隆抗体、杂交瘤细胞株及应用
WO2023161291A1 (en) 2022-02-22 2023-08-31 Araris Biotech Ag Peptide linkers comprising two or more payloads

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5186090A (en) 1989-02-23 1990-09-26 Colorado State University Research Foundation Gnrh analogs for destroying gonadotrophs
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
EP1661584A1 (en) 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
EP2015782A4 (en) * 2006-04-12 2010-04-07 Crosslink Genetics Corp COMPOSITIONS AND METHODS FOR MODULATING GENE EXPRESSION
ATE521366T1 (de) 2006-05-27 2011-09-15 Faulstich Heinz Dr Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen
KR20110140124A (ko) * 2009-04-08 2011-12-30 하인즈 파울스티히 암치료용 아미톡신-활성 표적 결합 부위
LT3192529T (lt) * 2009-04-08 2020-06-25 Faulstich, Heinz, Dr. Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
US20150218220A1 (en) 2012-09-12 2015-08-06 Brian Alan MENDELSOHN Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase

Also Published As

Publication number Publication date
AU2011307195A1 (en) 2013-04-11
RU2013119960A (ru) 2014-11-10
CN103153345A (zh) 2013-06-12
IL225200A0 (en) 2013-06-27
JP2013544231A (ja) 2013-12-12
MX344010B (es) 2016-12-02
CN103153345B (zh) 2016-08-10
BR112013007577B1 (pt) 2021-05-04
ES2402254T3 (es) 2013-04-30
RU2601411C2 (ru) 2016-11-10
EP2436398B1 (en) 2013-01-23
IL225200A (en) 2016-09-29
CA2812460A1 (en) 2012-04-05
US9399681B2 (en) 2016-07-26
SG189189A1 (en) 2013-05-31
KR102041166B1 (ko) 2019-11-06
US20130259880A1 (en) 2013-10-03
JP5977241B2 (ja) 2016-08-24
NZ608142A (en) 2014-10-31
EP2621536A1 (en) 2013-08-07
UA111341C2 (uk) 2016-04-25
CA2812460C (en) 2019-02-05
AU2011307195B2 (en) 2015-12-10
BR112013007577A2 (pt) 2016-08-02
KR20130129193A (ko) 2013-11-27
WO2012041504A1 (en) 2012-04-05
EP2621536B1 (en) 2017-09-13
ES2651745T3 (es) 2018-01-29
EP2436398A1 (en) 2012-04-04

Similar Documents

Publication Publication Date Title
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
MX2013010286A (es) Conjugados de amatoxinas con enlaces mejorados.
MX2015011583A (es) Derivados de amatoxina.
EA201300039A1 (ru) Оптимизированная с помощью эндосомолитических средств система доставки in vivo конъюгатов нуклеиновой кислоты
NZ720743A (en) Peptidomimetic compounds and antibody-drug conjugates thereof
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
IN2014CN04961A (es)
IN2012DN03025A (es)
TN2015000396A1 (en) Antibody drug conjugates
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2012000575A (es) Conjugados de epsilon-polilisina y uso de los mismos.
EA201890915A1 (ru) Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
NZ701573A (en) Carriers for improved drug delivery
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
MX2018013332A (es) Conjugados de pirrolobenzodiazepina diana.
NZ708171A (en) Oligonucleotide conjugates
MX362970B (es) Pirrolobenzodiazepinas y conjugados de las mismas.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2009100194A3 (en) Camptothecin-binding moiety conjugates
UA111711C2 (uk) Засіб імунотерапії деяких видів пухлин, у тому числі раку шлунково-кишкового тракту і раку шлунка
EP2303337A4 (en) MEDICAMENT-LIGAND SMALL MOLECULE CONJUGATES FOR TARGETED CANCER TREATMENT
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
MX2012010448A (es) Conjugados de carbohidrato-poli aminoacido-farmaco.
EP2519542A4 (en) ANTI-CDH3 ANTIBODY AND ITS USE

Legal Events

Date Code Title Description
FG Grant or registration